Product
Eureka
For R&D, Eureka makes reading and utilizing patents & technical documents easy.
Eureka AIR
Designed for self-driven R&D workflows. Generate viable solutions, solve complex R&D challenges, empower your innovation with AI.
Eureka Materials
Designed for material experts only. Revolutionize your material R&D, from search, analyze, to developing new materials.
Feature
TechResearch
Generate reliable direction feasibility study reports for your R&D in just a few steps.
TechSeek
Discover and master advanced knowledge NOW. Basics, ideas, possibilities, all at once.
TechMind
As an expert in R&D Theories, TechMind can generates customized viable solutions instantly.
TechRisk
Analyze your overall solution with one click, know your potential R&D risks in advance.
TechMonitor
Get weekly tech updates, stay abreast of the latest tech innovations and key insights.
Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
46results about "Insulin-like growth factor binding protein" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
IGF-binding protein-derived peptide or small molecule
InactiveUS6914049B2Reducing tumor invasivenessReducing and inhibiting vascular restenosisSenses disorderNervous disorderPeptideSmall molecule
New compositions based on IGF-binding protein sequences are provided. New tools for high-throughput research are provided. New methods for the treatment of human disease are provided. IGFBP-3-derived peptide or small molecule is administered to subjects having disease, thereby alleviating the symptoms of the disease.
Owner:BIOEXPERTISE +1
IGF-binding protein-derived peptide
InactiveUS6887851B2Reducing tumor invasivenessReducing and inhibiting vascular restenosisBiocidePeptide/protein ingredientsSmall moleculePeptide
New compositions based on IGF-binding protein sequences are provided. New tools for high-throughput research are provided. New methods for the treatment of human disease are provided. IGFBP-3-derived peptide or small molecule is administered to subjects having disease, thereby alleviating the symptoms of the disease.
Owner:ENMODULIN INC +1
Specifically-targeted swine IGFBP3 gene sgRNA targeting sequence and application
The invention relates to a sgRNA targeting sequence and application, in particular to a specifically-targeted swine IGFBP3 gene sgRNA targeting sequence and application. The sgRNA targeting sequence is CGTCTCGCGCTTGGACTCAG. By the sgRNA targeting sequence, an IGFBP3 gene can be knocked out or edited through a CTISPR / Cas9 system so as to eliminate IGFBP3 expression to lay the foundation for preparation of IGFBP3 transgenic swine. The specifically-targeted swine IGFBP3 gene sgRNA targeting sequence is applied to the field of gene engineering.
Owner:NORTHEAST AGRICULTURAL UNIVERSITY
IGF antagonist peptides
Peptides are provided that antagonize the interaction of IGF-1 with its binding proteins, insulin receptor, and IGF receptor. These IGF antagonist peptides are useful in treating disorders involving IGF-1 as a causative agent, such as, for example, various cancers.
Owner:GENENTECH INC
Insulin-like growth factor agonist molecules
Owner:GENENTECH INC
Antisense insulin-like growth factor binding protein (IGFBP)-2-oligodeoxynucleotides for prostate and other endocrine tumor therapy
InactiveUS7196067B2Reduce spreadDelay progression to androgen independenceSugar derivativesPeptide/protein ingredientsMammalAntisense oligodeoxynucleotides
Compositions and a method are provided for the treatment of prostate and other endocrine tumors in mammals, including humans, by administration of an antisense oligodeoxynucleotide (ODN) which is complementary to a portion of the gene encoding IGFBP-2. Using the Shionogi tumor model in vitro and in vivo, the administration of such an ODN was shown to reduce proliferation of tumor cells, and also to delay the progression to androgen independence. Thus, treatment of prostate and other hormone-regulated cancer in mammals, including humans, and delay of the progression of prostate tumors to androgen independence is accomplished by administering to the mammal a therapeutically effective amount of an antisense oligodeoxynucleotide which is complementary to a portion of the nucleic acid sequence encoding IGFBP-2 and which reduces the amount of IGFBP-2 in the treated cells.
Owner:THE UNIV OF BRITISH COLUMBIA
IGF antagonist peptides
Peptides are provided that antagonize the interaction of IGF-1 with its binding proteins, insulin receptor, and IGF receptor. These IGF antagonist peptides are useful in treating disorders involving IGF-1 as a causative agent, such as, for example, various cancers.
Owner:GENENTECH INC
Metal-binding therapeutic peptides
InactiveUS7611893B2Reduce the burden onEnhancing existing chemotherapeutic cocktailsOrganic active ingredientsSenses disorderLiving cellBiology
Owner:ENMODULIN INC
IGF antagonist peptides
Owner:GENENTECH INC
CCN3 peptide
InactiveUS20100004169A1Increase kinase activityActivity be increased and decreasedCompound screeningApoptosis detectionDiseasePeptide sequence
The present application relates to nucleic acid and peptide sequences of CCN3 and derivatives and fragments thereof useful in the treatment of disease, in particular tumours and / or for use as a clinical marker.
Owner:QUEENS UNIV OF BELFAST
Insulin-like growth factor agonist molecules
Owner:GENENTECH INC
IGF-I responsive gene and use thereof
InactiveUS20060177906A1Peptide/protein ingredientsReceptors for hormonesMotilityNucleic acid sequencing
Owner:UNIV COLLEGE CORK NAT UNIV OF IRELAND CORK
Methods for delivering MBD peptide-linked agent into cells under conditions of cellular stress
The present invention is related to methods of delivering MBD peptide-linked agents into live cells. The methods described herein comprise contacting MBD peptide-linked agents to live cells under a condition of cellular stress. The methods of the invention may be used for therapeutic or diagnostic purposes.
Owner:BIOEXPERTISE
Igfbp-3 derivatives and uses thereof
Owner:INST NAT DE LA SANTE & DE LA RECHERCHE MEDICALE (INSERM)
Compounds, compositions and uses thereof for improvement of bone disorders
Owner:AMOLYT PHARMA
Insulin-Like Growth Factor Binding Protein-4 Compounds and Methods for Inhibiting Angiogenesis and Tumor Growth in Mammalian Cells
InactiveUS20090048158A1Inhibit angiogenesisPeptide/protein ingredientsDepsipeptidesAngiogenesis growth factorWilms' tumor
Owner:MORENO MARIA J +3
Purified rhlGF-I/rhlGFBP-3 complexes and their method of manufacture
Complexes of IGF-I and IGFBP-3 with new levels of purity are provided. Chromatographic techniques have been developed that remove contaminants, such as mass and charge variants of IGFBP-3. The new techniques enable the production of high-quality pharmaceutical compositions comprising IGF-I / IGFBP-3 complexes.
Owner:INSMED INC
Corrective roles of insulin-like growth factor-binding protein-3 in cardiomyopathy
ActiveUS8802629B1Promote wound healingPromote angiogenesisPeptide/protein ingredientsDepsipeptidesInjury mouthAngiogenesis Factor
The invention relates to methods of promoting the expression of pro-angiogenic factors and decreasing the expression of anti-angiogenic and fibrotic factors in a cell, as well as the treatment of cardiomyopathy and wounds.
Owner:RUTGERS THE STATE UNIV
Compounds, compositions and uses thereof for improvement of bone disorders
ActiveUS20180230191A1Reduce usageUseful in treatmentPeptide/protein ingredientsSkeletal disorderDiseasePeptide
Owner:AMOLYT PHARMA
Identification and medical applications of Anti-citrullinated-protein antibodies in rheumatoid arthritis
PendingUS20200386754A1High prevalenceHydrolasesImmunoglobulins against cytokines/lymphokines/interferonsInsulin-like growth factorPancreatic hormone
Compositions and methods for detection of anti-citrullinated protein antibodies (ACPAs) in rheumatoid arthritis (RA) patients. Patient samples known or suspected of containing ACPAs were probed against citrullinated proteins, and antibody responses to 190 citrullinated proteins in 20 RA patients were investigated. Unique antibody reactivity patterns in both clinical anti-cyclic citrullinated peptide assay positive (CCP+) and negative (CCP−) RA patients were observed. At individual antigen levels, six novel antibody / antigen complexes were discovered and validated against specific citrullinated antigens (Myelin Basic Protein (MBP), osteopontin (SPP1), flap endonuclease (FEN1), insulin like growth factor binding protein 6 (IGFBP6), insulin like growth factor I (IGF1) and stanniocalcin-2 (STC2)) in RA patients. Identification of immune-dominant epitope(s) for citrullinated MBP was also performed. The identified biomarkers have high specificity, especially MBP.
Owner:ARIZONA STATE UNIVERSITY +1
Radiation exposure diagnostic marker igfbp-5, composition for radiation exposure diagnosis by measuring the expression level of the marker, radiation exposure diagnostic kit comprising the composition, and method for diagnosing radiation exposure using the marker
InactiveUS20140357517A1Increased radiation sensitivityImprove expression levelPeptide/protein ingredientsLibrary screeningRadiation sensitivityRadiation exposure
The present disclosure provides a composition for radiation exposure diagnosis including an agent for measuring an expression level of an insulin-like growth factor-binding protein-5 (IGFBP-5) gene at an mRNA or the protein and a kit for radiation exposure diagnosis. Methods of diagnosing radiation exposure as well as methods for screening an agent for enhancing radiation sensitivity or for radiation protection are disclosed. Also provided are compositions for enhancing radiation sensitivity and / or radiation protection.
Owner:KOREA INST OF RADIOLOGICAL & MEDICAL SCI
Cxcl12 (chemokine (c-x-c motif) ligand 12) and igfbp2 inhibitors for the application in the treatment of diabetes mellitus associated pancreatic cancer
InactiveUS20160215053A1Facilitated DiffusionSuppress immune responseOrganic active ingredientsVertebrate antigen ingredientsChronic hyperglycemiaIncreased glucose level
The subject of the invention is the application of CXCL12 (Chemokine (C-X-C motif) Ligand 12) and IGFBP2 inhibitors for the treatment of diabetes mellitus associated pancreatic cancer. The core of this invention is the discovery that the chronically increased glucose levels (chronic hyperglycemia) could may an important role in the development of the pancreatic cancer and that the development of the pancreatic cancer due to chronic hyperglycemia or an already developed pancreatic cancer may be prevented / inhibited / delayed by the inhibition of CXCL12 and IGFBP2. In addition the subject of the invention is the production of inhibitors for the application as a treatment of diabetes mellitus associated pancreatic cancer and pharmaceutical drugs containing the inhibitors.
Owner:FIRNEISZ GABOR +2
Method for treating cartilage disorders
The present invention relates to a method for the treatment of a cartilage disorder, including cartilage damaged by injury or degenerative cartilagenous disorders. The method involves contacting the cartilage with an IGF-1 analog with altered affinity for IGF-binding proteins (IGFBPs) or an IGFBP displacer peptide that prevents the interaction of an IGF with an IGFBP and does not bind to a human IGF receptor.
Owner:GENENTECH INC
Inhibitors and Use Thereof in Cancer Treatment
PendingUS20220259265A1Avoid repairsIncreased chemosensitivityOrganic active ingredientsPeptide/protein ingredientsCancer cellPancreatic hormone
The invention generally relates to inhibitors of DNA double strand break (DSB) repair in cancer cells exposed to DNA-damaging chemotherapy drugs or radiotherapy. In particular, agents that inhibit binding between insulin-like growth factor binding protein-3 (IGFBP-3) and non-POU (pituitary-specific Pit-1, octamer-binding proteins Oct-1 and Oct-2, and neural Unc-86) domain-containing octamer-binding protein (NONO) and methods of using such agents to enhance chemosensitivity or radiosensitivity in cancer treatment are disclosed.
Owner:THE UNIV OF SYDNEY
KOC1-derived peptide and vaccine including same
ActiveUS10576102B2Reduction in size and spreading and metastatic abilityRelief of clinical symptomsPeptide/protein ingredientsGenetic material ingredientsCancer preventionInducer Cells
Owner:ONCOTHERAPY SCI INC
TNF receptor death domain ligand proteins and inhibitors of ligand binding
InactiveUS7109307B2Inhibit inflammationAvoid deathPeptide/protein ingredientsImmunoglobulins against cytokines/lymphokines/interferonsNucleotideDeath domain
Owner:GENETICS INST INC
IGF-binding protein-derived peptide or small molecule
InactiveUS20050209155A1Reduce intrusionReduce spreadSenses disorderNervous disorderDisease causeSmall molecule
New compositions based on IGF-binding protein sequences are provided. New tools for high-throughput research are provided. New methods for the treatment of human disease are provided. IGFBP-3-derived peptide or small molecule is administered to subjects having disease, thereby alleviating the symptoms of the disease.
Owner:BIOEXPERTISE
Mutants of IGF Binding Proteins and Methods of Production of Antagonists Thereof
InactiveUS20090117662A1High affinityGood treatment effectPeptide/protein ingredientsPeptide preparation methodsInsulin-like growth factorX-ray
The present invention provides a crystal suitable for X-ray diffraction, comprising a complex of insulin-like growth factor I or II (IGF) and a polypeptide consisting of the amino acids 40-92 of IGFBP-5 or a fragment thereof consisting at least of the 9th to 12th cysteine of IGFBP-5 methods for the determination of the atomic coordinates of such a crystal; IGFBP mutants with enhanced binding affinity for IGF-I and / or IGF-II, and methods to identify and optimize small molecules which displace IGFs from their binding proteins.
Owner:BEISEL HANS GEORG +7
Methods and compositions for treating a disease or disorder
PendingUS20220235136A1Organic active ingredientsPeptide/protein ingredientsDiseaseSignalling pathways
Owner:YALE UNIV +1
Who we serve
- R&D Engineer
- R&D Manager
- IP Professional
Why Eureka
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Social media
Eureka Blog
Learn More Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com